Active	Status	Sponsor type	Region	Phase	Filter
14 Active 26 Inactive 40 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Arrieta, Oscar
NCT03779191: Alectinib in Combination With Bevacizumab in ALK Positive NSCLC	Completed	2	41	RoW	Alectinib, Alecensa, Bevacizumab, Avastin	Instituto Nacional de Cancerologia de Mexico, Roche Pharma AG	ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Neoplasm of Lung	08/22	10/22
Rodriguez, Oscar A
NCT03779191: Alectinib in Combination With Bevacizumab in ALK Positive NSCLC	Completed	2	41	RoW	Alectinib, Alecensa, Bevacizumab, Avastin	Instituto Nacional de Cancerologia de Mexico, Roche Pharma AG	ALK Gene Rearrangement Positive, Non-Squamous Non-Small Cell Neoplasm of Lung	08/22	10/22